Lexon UK Ltd, Moclobemide 150mg tablets defect

Class 4 medicines defect notification: The MHRA has published a Class 4 medicines defect notification for moclobemide 150mg tablets.

Published: 25 November 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect notification for moclobemide 150mg tablets. Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the cartons for specified batches are missing important updated safety information.

Pharmacists are advised to review the information contained within the medicines defect notification and take this into account when dispensing this product, especially for new patients. If the specified medicine is dispensed, ensure that patients are aware of the missing information. Please see updated PIL for the correct information.

Further information, advice and details of the affected batches can be found on the MHRA website.

No documents available for download.

Related articles

Recall of Quetiapine oral suspension (unlicensed medicine), manufactured by Eaststone Limited

Class 1 medicines recall notification: The MHRA has published a Class 1 medicines recall for Quetiapine oral suspension (unlicensed medicine) due to a potential for overdosing.

Read more

Mercury Pharmaceuticals Ltd, Paliperidone Mercury Pharma prolonged-release suspension for injection in pre-filled syringes recall

Class 2 medicines recall: The MHRA has published a Class 2 medicines recall for Paliperidone 50mg, 75mg, 100mg and 150mg prolonged-release suspension for injection in pre-filled syringes.

Read more